InterMed Discovery achieves Proof-of-Principle for IMD-026260
Small molecule anti-cancer drug candidate based on Hif-1 modulation
IMD-026260 initially demonstrated very high in vitro efficacy in a broad panel of tumor cell monolayer assays as well as in colony forming assays. From these tests, high scores of tumor selectivity were observed towards a variety of cancer cell lines derived from human prostate, lung, colon and uterus tumors. Subsequently, xenograft studies proved potent in vivo efficacy at single-digit mg/kg dosage levels.
"Based on the high cytotoxic potential and innovative mechanism of action, IMD-026260 is a promising drug candidate not only for the treatment of lung, breast, prostate, colon and uterine cancers, but also for the treatment of metastases," said Bernard Becker, Managing Director of InterMed Discovery.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.